After Scylla and Charybdis: The many possible futures of MFN drug pricing

Published on November 6, 2026

Most Favored Nation policy is now a commercial reality. We examine the possible scenarios of MFN drug pricing.

Since President Trump's executive order on MFN pricing just 12 months ago, the policy has already taken the pharmaceutical industry on a remarkable journey of twists, turns, and escalating consequences. 

What began as a policy thought experiment has hardened into a commercial reality that stakeholders can no longer ignore. And while the outlines of MFN are far clearer today than they were a year ago, the road ahead may be even more uncertain than the one behind us. Much like Odysseus on his voyage home, pharmaceutical companies now face a series of hazards and irreversible choices that will determine whether they have navigated wisely or steered toward financial ruin.

The fate of GLOBE and GUARD

The first major decision point on this next leg of the voyage is the fate of…

Blog header_The possible scenarios of MFN drug pricing in pharma

Continue reading on website
Other news

Beyond rarity: Building RWE strategies for the next generation of orphan drug markets

November 6, 2026
Rarity is no longer enough. As orphan drug markets become more crowded and payers challenge evidence, price, and durability claims with increasing scrutiny, manufacturers need to rethink how they prove value. This article explores how to use real-world evidence as a strategic access lever to help orphan assets defend unmet need, quantify comparative benefit, address long-term uncertainty, and diff

The economics of data products and what successful monetization generates

December 1, 2026
In our first blog, we looked at banks wrestling with what data they can actually monetize. Retail, by contrast, addressed this question years ago, and the economics are striking. Average retail operations run on tight 2 to 4% profit margins, and data businesses built on that same infrastructure consistently hit 75 to 90% margins.These are fundamentally different business models operating within th